Antimicrobial resistance remains one of the most pressing threats to modern medicine, and researchers around the world are racing to find alternatives to conventional antibiotics. One of the most promising candidates to emerge in recent decades is LL-37, the only cathelicidin antimicrobial peptide found in humans. This small protein fragment is part of the innate immune system, patrolling the skin and mucosal surfaces where it punches holes in bacterial membranes and orchestrates immune responses. Because LL-37 attacks the fundamental architecture of microbial membranes, bacteria find it far harder to develop resistance than they do against antibiotics that target specific enzymes. Yet despite its broad-spectrum potency and low propensity for resistance development, LL-37 has struggled to reach the clinic, largely because producing it in useful quantities is expensive and technically difficult.
A new study published in Applied Microbiology and Biotechnology offers a creative solution to both the production problem and the targeting problem at once. A team led by Laura Colomina-Alfaro and Antonella Bandiera at the University of Trieste, working with colleagues at Empa, the Swiss Federal Laboratories for Materials Science and Technology, King’s College London and the University of Birmingham, has engineered a fusion polypeptide called H1FK16. The construct genetically fuses FK16, a bioactive fragment derived from LL-37, to a human elastin-like polypeptide carrier known as HELP. The work, published as an open-access article in September 2026, demonstrates that this fusion system can serve as a versatile platform for biocompatible materials that selectively target pathogenic microorganisms through enzymatically triggered release of their antimicrobial payload.
The logic behind the carrier is elegant. Traditional chemical synthesis of antimicrobial peptides relies on solid-phase peptide chemistry, which becomes prohibitively costly at scale and generates significant waste. Recombinant expression, in which bacteria are genetically instructed to manufacture the desired protein, offers a cost-effective and scalable alternative. However, antimicrobial peptides are toxic to the host bacteria used to produce them, and they often fold poorly or aggregate, leading to disappointing yields. The HELP carrier sidesteps these obstacles in several ways simultaneously. Because the antimicrobial domain is tethered to a large, inert carrier protein, it cannot damage the producing cells. The carrier also enhances the solubility of the attached peptide, keeping it in a form that the bacterial protein-making machinery can handle.
Perhaps the most remarkable property of elastin-like polypeptides is their thermoresponsive phase-transition behavior. Below a characteristic transition temperature, the polypeptide remains dissolved in solution; above it, it reversibly aggregates out of the liquid. This means researchers can purify the fusion protein simply by warming and cooling the bacterial lysate in a cycle, spinning down the aggregated protein and redissolving it, without expensive chromatography columns. In previous studies, this approach effectively mitigated host toxicity, enhanced solubility and enabled simple purification of antimicrobial domains. In the new work, the production yield of H1FK16 was comparable to that of the carrier alone, averaging 180 milligrams of fusion protein per liter of bacterial culture, a figure that bodes well for industrial scalability.
FK16 itself is a sixteen-residue fragment of LL-37 that retains the peptide’s essential antimicrobial activity. The design team made a crucial decision when assembling the gene: they positioned an upstream glutamic acid residue at the junction between the carrier and the antimicrobial domain. This single amino acid acts as a molecular tripwire. Glutamyl endopeptidase, a proteolytic enzyme secreted by Staphylococcus aureus as part of its virulence arsenal, cleaves proteins specifically after glutamate residues. In other words, the very pathogen the material is designed to fight carries the key to its own destruction. When S. aureus is present and secreting its virulence-associated protease, the enzyme snips the fusion protein at the engineered site, liberating free FK16 exactly where it is needed.
This enzymatically triggered release transforms the fusion protein from a simple antibiotic into a smart, pathogen-responsive material. In its intact form, H1FK16 is non-cytotoxic, meaning it can coexist harmlessly with human cells and tissues. Only when a disease-causing bacterium betrays its presence by secreting glutamyl endopeptidase does the antimicrobial warhead detach and become active. Such triggered targeting addresses one of the central dilemmas of antimicrobial therapy: how to deploy a potent membrane-disrupting agent without harming beneficial microbes or host tissue. The strategy effectively lets the pathogen’s own biology decide when and where the drug should be unleashed.
The researchers put the released FK16 through rigorous functional testing. The liberated peptide retained its antimicrobial activity against both Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, exhibiting a minimum inhibitory concentration of 2.5 micromolar, a value comparable to figures reported in the literature for chemically synthesized versions of the peptide. This is a critical validation: it shows that recombinant production, fusion to a large carrier and enzymatic cleavage do not compromise the peptide’s ability to kill bacteria. The recombinant product is functionally indistinguishable from its chemically made counterpart, but potentially far cheaper to manufacture at scale.
Beyond killing planktonic, free-floating bacteria, the team also examined how H1FK16 treatment affected biofilms, the stubborn, matrix-encased bacterial communities that coat medical implants, chronic wounds and catheters, and that resist conventional antibiotics with alarming tenacity. Their experiments showed that treatment with the fusion polypeptide reduced biofilm biomass, one of the three key findings highlighted by the authors alongside the recombinant production of FK16 and the enzyme-triggered cleavage process. Biofilm eradication is a notoriously difficult goal, and any platform that can both prevent and disrupt these protective communities could have significant clinical value in the management of device-related and chronic infections.
The implications extend beyond a single peptide. Because the HELP carrier is genetically encoded, the same platform could in principle accommodate other antimicrobial domains, simply by swapping the fused sequence. The glutamic acid trigger could likewise be exchanged for cleavage sites recognized by other pathogen-specific proteases, creating a family of materials that each respond to a different microbial signature. Such materials could be incorporated into wound dressings, implant coatings or tissue-engineered scaffolds, lying dormant until a pathogen’s own enzymes activate them. The biocompatibility of the human-derived elastin-like carrier further supports applications in direct contact with tissue, and the study’s cytotoxicity findings suggest the intact fusion is safe for surrounding cells.
The research was supported by the Horizon Europe project STOP under grant agreement number 101057961, the NextGenerationEU project iNEST, and the Swiss State Secretariat for Education, Research and Innovation. It represents a convergence of materials science, microbiology and synthetic biology, and it arrives at a moment when the clinical pipeline for new antibiotics is dangerously thin. Challenges certainly remain before H1FK16 or its descendants reach patients: the stability of the fusion protein in complex biological fluids, the efficiency of enzymatic release in vivo, and the immunological consequences of long-term exposure all require further study. But the core demonstration stands. A human antimicrobial peptide can be produced cheaply by bacteria, rendered harmless by fusion to a thermoresponsive carrier, and reactivated on demand by the proteolytic machinery of the very pathogens it is meant to destroy. In the escalating arms race between medicine and resistant microbes, weapons that wait patiently for the enemy to disarm them first may prove to be among the most ingenious yet.
Subject of Research: Recombinant production of a cathelicidin-derived antimicrobial fusion polypeptide with pathogen-triggered peptide release
Article Title: Evaluation of a cathelicidin derivative fusion polypeptide for pathogen-targeted antimicrobial approach
Article References: Colomina-Alfaro, L., Lee, M., Zhang, S., Sist, P., Urbani, R., Shaalan, A., Di Silvio, L., Stamboulis, A., Ren, Q., & Bandiera, A. (2026). Evaluation of a cathelicidin derivative fusion polypeptide for pathogen-targeted antimicrobial approach. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14037-z
Image Credits: AI Generated
DOI: 10.1007/s00253-026-14037-z
Keywords: antimicrobial peptides, LL-37, cathelicidin, FK16, elastin-like polypeptide, recombinant expression, Staphylococcus aureus, glutamyl endopeptidase, biofilm, antimicrobial resistance, fusion protein, triggered drug release
Cite Scienmag News
APA
MLA
Chicago
Drew Townsend. (September 25, 2026). Engineered Fusion Protein Delivers Antimicrobial Peptides Only Where Dangerous Bacteria Strike. Scienmag. https://scienmag.com/engineered-fusion-protein-delivers-antimicrobial-peptides-only-where-dangerous-bacteria-strike/
Drew Townsend. “Engineered Fusion Protein Delivers Antimicrobial Peptides Only Where Dangerous Bacteria Strike.” Scienmag, 25 September 2026, https://scienmag.com/engineered-fusion-protein-delivers-antimicrobial-peptides-only-where-dangerous-bacteria-strike/. Accessed 26 September 2026.
Drew Townsend. “Engineered Fusion Protein Delivers Antimicrobial Peptides Only Where Dangerous Bacteria Strike.” Scienmag. September 25, 2026. https://scienmag.com/engineered-fusion-protein-delivers-antimicrobial-peptides-only-where-dangerous-bacteria-strike/
Copy citation
Download RIS
Tags: antimicrobial peptide therapeutics developmentantimicrobial peptidesAntimicrobial Resistanceantimicrobial resistance solutionsbiofilmcathelicidinelastin-like polypeptideengineered fusion proteins for targeted bacterial killingFK16fusion proteinfusion protein technology in microbiologyglutamyl endopeptidaseinnate immune system peptidesinnovative antimicrobial strategiesLL-37LL-37 antimicrobial peptideovercoming production challenges of antimicrobial peptidesrecombinant expressionreducing antibiotic resistance with fusion proteinsselective delivery of antimicrobial peptidesStaphylococcus aureustargeted antimicrobial therapytriggered drug release
